Background: Due to increasing use of new oral anticoagulants (NOACs), clinicians are faced more and more frequently with clinical issues related to these drugs. Objective: The objective of this publication is to make practical suggestions for the perioperative management of NOACs as well as for their handling in overdoses and bleedings. Recommendations: In elective surgery and creatinine clearance ≥ 50 ml/ min, a NOAC should be discontinued 24-36 h before the intervention, and even earlier in case of reduced kidney function. In emergency interventions that cannot be delayed, the management is dependent on the NOAC plasma levels. With levels ≤ 30 ng/ml, surgery can be performed. With levels >30 ng/ml, reversal agents should be considered. In low bleeding risk surgery, NOACs can be re-started 24 h after the intervention, which is prolonged to 48-72 h after surgery with high bleeding risk. In case of NOAC overdose and minor bleedings, temporary discontinuation and supportive care are usually sufficient to control the situation. In severe or lifethreatening bleedings, nonspecific and specific reversal agents should be considered.
Introduction
New oral anticoagulant (NOAC) agents have been increasingly used in the prevention and treatment of thromboembolic events in the last few years. The four NOACs currently available in Europe directly target and inhibit either factor Xa (apixaban, edoxaban and rivaroxaban) or thrombin (dabigatran).
In addition to having numerous practical advantages -simple dosage schemes and no need for laboratory monitoring -over previous treatments using vitamin K antagonists (VKAs), NOACs are also demonstrating clinical benefits. Meta-analyses and systematic reviews comparing NOACs to the VKA warfarin provided evidence of NOACs having similar to superior efficacy in preventing stroke and systemic thromboembolic events in patients with non-valvular atrial fibrillation (nvAF), while significantly reducing the likelihood of major and especially intracranial bleeding [1] [2] [3] [4] [5] .
While all four available NOACs are indicated and have proven efficacy in patients with nvAF as well as for treatment and secondary prophylaxis of deep-vein thrombosis and pulmonary embolism [6] [7] [8] [9] [10] [11] [12] , only three (dabigatran, apixaban, rivaroxaban) have so far been cleared for the prevention of thromboembolic events after major knee or hip surgery in Europe and the US [13] [14] [15] [16] [17] [18] . Only two (apixaban, rivaroxaban) are currently available for this indication in Switzerland [6, 7, 19] (table 1) .
The intra-and postoperative bleeding risk is influenced by the product and application characteristics of the NOAC, patient-related factors, and the type of intervention. High bleeding risk means that a patient is at risk of losing a large amount of blood or bleeding occurs in a critical, closed space with potentially severe consequences.
NOACs: Approved Indications and Dosages
All NOACs block an activated coagulation factor, either FXa (apixaban, edoxaban, rivaroxaban) or FIIa (thrombin; dabigatran), thus halting the coagulation cascade and preventing clot formation. Despite the similar mode of action, the different NOACs vary in several practically relevant aspects, such as their approved indications, pharmacokinetic properties, and dosage schemes. In table 1 the approved indications and corresponding dosage schemes recommended by Swiss, European and US American drug information agencies are listed. However, for some patients an adaptation of the dosage is advised, as age, body weight, and renal or liver functions can have an influence on the drug's dynamics [6] [7] [8] [9] 20] .
Pharmacokinetic Profiles
In order to perform surgery at a time of minimal bleeding risk, the timing of last intake and the pharmacokinetic properties of the NOAC used have to be considered, some of which are summarized in table 2. Especially the time to peak concentration (T max /C max ), the half-life (T 1/2 ) and the elimination pathway are important pieces of information that should be factored in patient management.
Drug Interactions
NOACs were developed to offer advantageous treatment alternatives to the VKAs [24, 25] . The reduction of drug/drug and drug/food interactions are among the most relevant advantages of NOACs over VKAs [24, 26] . As NOACs are partially eliminated through P-glycoproteins (P-gp) transport proteins and cytochrome P450 enzymes, there is still a potential of interference with drugs that use the same pathways. Such interactions may ultimately lead to over-or under-anticoagulation [27] . Recommendations are mainly based on pharmacokinetic studies measuring plasma levels of drugs with the same metabolic pathways as NOACs, as only little data is available on the bleeding risk of combining NOACs with other medications. A new population-based cohort study with over 90,000 atrial fibrillation (AF) patients found a high risk of major bleeding for NOAC patients who were also taking amiodarone and fluconazole, in line with their respective pharmacokinetic data. Surprisingly, the higher risk of major bleeding was also prevalent for NOAC patients taking rifampicin and phenytoin, which, according to their pharmacokinetic profiles, lead to lower NOAC plasma levels -an unexplained fact caused by an un- Rivaroxaban is also admitted for CrCl 15-29 ml/min; careful application required, no dosage recommendation. 9 Can be taken independent of food, whereas 15 mg and 20 mg should be taken with food to assure bioavailability. 10 Duration of treatment: major hip surgery 5 weeks, major knee surgery 2 weeks.
11
Age ≥ 80 years, or patients receiving concomitant verapamil.
12
Duration of treatment: hip replacement 28-35 days, knee replacement 10 days. 13 Patients with at least two of the following criteria: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dl (133 µmol/l).
14 After at least 6 months of treatment for DVT or PE. 15 Duration of treatment: hip replacement 32-38 days, knee replacement 10-14 days. 16 EMA advises that 'edoxaban should only be used in patients with nvAF and high creatinine clearance after careful evaluation of the individual thromboembolic and bleeding risk'. 17 Patients with one or more of the following clinical factors: CrCl 15-50 ml/min, body weight ≤ 60 kg, concomitant use of P-gp inhibitors. 18 Patients with high risk of recurrent DVT/PE consider administering 1 × 20 mg/day. 19 In combination with acetylsalicylic acid (1 × 75-100 mg/day) or acetylsalicylic acid (1 × 75-100 mg/day) in addition to either clopidogrel (1 × 75 mg/day) or a standard dose of ticlopidine (once daily). 20 In combination with acetylsalicylic acid (1 × 75-100 mg/day).
21
CrCl>30 ml/min. 22 CrCl between 15 and 30 ml/min. 23 If given with P-gp inhibitors dronedarone or systemic ketoconazole. 24 Duration of treatment: hip replacement 28-35 days. 25 Patients with at least two of the following criteria: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dl. 26 Duration of treatment: hip replacement 35 days, knee replacement 12 days. 27 FDA provides a boxed warning that "edoxaban should not be used in patients with CrCl > 95 ml/min. 28 For patients with CrCl 15-50 ml/min. 29 If CrCl > 50 ml/min. known mechanism. Bleeding rates when taking other drugs that either inhibit CYP 3A4 or compete for P-gp, were not found to be increased [28] . Although this study with a Taiwanese population may not be generalized to Western patients, one should be mindful of amiodarone, especially in the perioperative setting, as it is a frequently used drug amongst NOAC users.
If co-administration of a NOAC with interacting agents cannot be avoided, then a monitoring could be beneficial before a surgical intervention [7, 22] . Details are summarized in table 3.
Disorders and Interventions with Increased Risk of Bleeding
The bleeding risk of a patient undergoing surgery depends on the type of intervention, the patient's individual characteristics, and the co-medication used. Disorders known to increase a patient's susceptibility to bleeding are shown in table 4.
Bleeding Risk of Surgical Interventions
Usually emergency surgery is associated with high or increased bleeding risk. Many surgical interventions also increase the thromboembolic risk. So, both risks -the one for bleeding and the one for thromboembolic eventsmust be balanced [30] . In table 5 bleeding and thromboembolic risks for common surgeries are listed.
Coagulation Tests / Monitoring
The NOACs' pharmacodynamic and pharmacokinetic profiles are well known, which makes their anticoagulation effects relatively predictable. Therefore, patients using NOACs do not require routine coagulation monitoring [6, 7, 9, 22, 31] .
However, in certain clinical circumstances specific coagulation tests are crucial, for example in situations of major bleeding, emergency surgery, stroke during treatment, or when the patient has developed renal failure [32] .
NOAC-specific tests have to be used which measure the plasma drug level (μg/ml) or the anti-FXa activity (IU/ T max = Time to maximum plasma concentration; T 1/2 = half-life, time to 50% of maximum plasma concentration; FXa = factor Xa; P-gp = P-glycoprotein; CYP3A4 = cytochrome P450 3A4; CYP450 = cytochrome P450; CYP2J2 = cytochrome P450 2J2; BRCP = breast cancer resistance protein; C max = maximum plasma concentration; AUC = area under the curve. ml). It is important to note, however, that prospective endpoint-driven studies assessing the effect of monitoring (± dosing adaptations based on these measurements) are lacking; as such, these measurements need to be performed and interpreted by specialists and should not be performed on a routine basis even in difficult/high-risk patients.
Also, in NOAC patients it may be indicated to carry out routine coagulation tests to assess the general coagulation status, especially when bleeding occurred or preoperatively. 
↑↑
(↑) Digoxin P-gp competition no effect no effect no effect no effect Diltiazem P-gp competition and weak CYP3A4 inhibition no effect ↑↑ no data (↑ 
↑↑↑ no data
Antiphlogistics Naproxen P-gp competition no data ↑↑ no effect no data Antacids H2B; PPI; Al-Mg-hydroxidegastrointestinal absorption ↓ no effect no effect no effect Others Carbamazepine, phenobarbital, phenytoin P-gp/BCRP and CYP3A4/CYP2J2 inducers ↓↓↓ ↓↓ ↓↓ ↓↓ P-gp = P-glycoprotein; CYP3A4 =cytochrome P450 3A4; BRCP = breast cancer resistance protein; CYP2J2 = cytochrome P450 2J2; GI ↑ up to 30%, ↑↑ up to 60%, ↑↑↑ up to 90%, ↑↑↑↑ > 90%. Table 6 may help with the interpretation of the test results, for which it is important to consider the time of last intake of the NOAC and the renal function [33] .
Prothrombin time (PT): Even though PT is not the most effective test available, it is still widely used in practice for screening [35] . PT is generally not a recommended test for the direct FXa inhibitors as there is a high variability and normal values do not exclude clinically relevant levels of the drugs [7, 8, 36, 37] . PT seems to be more sensitive towards rivaroxaban than to other FXa inhibitors [6, 33, 38] . PT is not sensitive to dabigatran, thus not recommended for its quantification [9] .
Activated partial thromboplastin time (aPTT): Due to widespread use, around the clock availability, low cost and relatively good sensitivity, aPTT may be used for the monitoring of dabigatran and as a screening test for the risk of bleeding [39] . Again, this test is not useful and not recommended for rivaroxaban, apixaban and edoxaban, as values show a high variability [6-8, 33, 36] .
The aPTT could be useful for an urgent assessment of the presence of dabigatran, although normal values might still indicate a presence of the drug [33, 40] .
Thrombin time (TT): This test is mainly useful to screen for the presence or absence of dabigatran, it is not useful for the direct FXa inhibitors [6-8, 34, 35] . A normal TT excludes the presence of dabigatran [41] .
Anti-FXa: For rivaroxaban, apixaban and edoxaban the most accurate measurement of plasma concentration is done with the anti-FXa assay using the specific drug as calibrator [6-8, 33, 34, 37] . In some clinics these tests are available 24/7 with results obtained in about 20 min, thus being a valid method even in urgent situations [22] .
Perioperative Management of NOACs

Elective Interventions
The objective of the peri-interventional management of patients already under NOAC before surgery is to minimize the peri-interventional risk for thromboembolism and bleeding.
Except for surgical interventions with very low risk of bleeding, NOAC therapy needs to be interrupted [42, 43] . Bridging is not recommended, as it has not been found to ↑Prolonged coagulation test or elevated anti-FXa plasma levels. 1 Prolonged, but no known relation with bleeding risk [29] . reduce thromboembolic events, but does increase the bleeding risk [42, [44] [45] [46] . In cases where interruption is not necessary, procedures should be undertaken at trough and not at peak levels of NOAC.
Recommendations about pre-interventional discontinuation of NOACs vary. While for interventions with low bleeding risk an interruption of NOACs of ≥24 h is often considered as sufficient, the proposed period of time for interventions with high bleeding risk is between 2 and 5 days, for dabigatran up to 7 days [20, 29, 47, 48] . These recommendations are not supported by clinical outcome data, but they rely on pharmacokinetic calculations using elimination half-lives to predict NOAC levels with minimal bleeding risk.
It is usually assumed that an interruption of two to three half-lives of the drug is safe for low and intermediate hemorrhagic risk, and of four to five half-lives for high bleeding risk and neuraxial anesthesia. Renal insufficiency therefore may prolong these periods, depending on the specific NOAC and its renal elimination.
The recently published CORDIA study examined the necessary discontinuation period to reach NOAC levels of ≤30 ng/ml, which were assumed to carry minimal bleeding risk [43] . Only 5% had NOAC levels of >30 ng/ml Dabigatran is eliminated mainly by the kidneys (80%); the delay should be prolonged in case of renal insufficiency. 2 Edoxaban depends on renal elimination more than rivaroxaban or apixaban. The delay should be increased in case of renal insufficiency. 3 In patients without comorbidities taking 10 mg/d and scheduled for low bleeding risk surgery, the delay can be shortened to 24 h. 1 Or the pre-operative, indicated dosage [51] . 2 For patients at high risk for thromboembolism, consider administration of a reduced dose of dabigatran (e.g. 1× 110-150 mg/day) on the evening after surgery and on the following day (first postoperative day) after surgery [59] . 3 For patients at high risk for thromboembolism, consider administration of a reduced dose of rivaroxaban (e.g. 1 × 10 mg/day) on the evening after surgery and on the following day (first postoperative day) after surgery [59] . 4 For patients at high risk for thromboembolism, consider administration of a reduced dose of apixaban (e.g. 2 × 2.5 mg/day) on the evening after surgery and on the following day (first postoperative day) after surgery [51] . 5 For patients at high risk for thromboembolism, consider administration of a reduced dose of edoxaban (e.g. 1 × 30 mg/day) on the evening after surgery and on the following day (first postoperative day) after surgery [51] . 6 LMWH such as enoxaparin 1 × 40 or 2 × 30 mg/day or mechanical prophylaxis such as intermittent pneumatic compression can be considered until therapeutic anticoagulation can be re-introduced [59] . NOACs in Anesthesiology Transfus Med Hemother 2019;46:282-293 DOI: 10.1159/000491400 after 49-2 h, and none >50 ng/ml. These figures were observed in patients with normal and reduced renal function, making it difficult to derive differentiated recommendations. For shorter discontinuation periods, there was a significant interindividual variability of plasma levels [43] . Another publication reported plasma levels of rivaroxaban that were higher than expected in patients with impaired kidney function (glomerular filtration rate < 60 ml/min) and with co-medication amiodarone [49] . In unclear situations, it remains reasonable to measure NOAC plasma levels.
Based on the limited available data, the NOAC-free interval before intervention/surgery for patients with low bleeding risk and normal renal function should be ≥24 h (for details see table 7). Provided there is no clinical evidence of disturbed hemostasis, the NOAC can be re-started the day after the intervention (table 8) . In patients with high bleeding risk and normal renal function the NOACfree interval before intervention/surgery is usually ≥48 h (for details see table 7), and re-start of the NOAC may take place on day 2 or 3 after the intervention, provided there are no signs of disturbed hemostasis or surgical contraindications [31] (table 8) .
The PAUSE trial is expected to provide more data on the timing of last intake, plasma levels, and clinical outcome of NOACs [50] .
Emergency Interventions
In emergency situations it is important to know the type of NOAC involved, the time of last intake, and the patient's renal function. If NOAC elimination is normal, the duration of action is 24 h for FXa antagonists and 24-36 h for dabigatran [23] (tables 2 and 7). Therefore, whenever possible, an intervention/surgery should be delayed by 24-48 h after last NOAC intake, in case of renal insufficiency even more (table 7) [51] . It may be helpful to know the NOAC plasma level, especially when the time of last intake is unknown or a relevant plasma level might still be present. The latter may be expected particularly in patients of advanced age (>75/80 years), low body weight (<60 kg), and/or compromised renal function (creatinine clearance < 50 ml/min). If it is unclear whether the test result represents a value from the ascending or descending slope of the NOAC plasma level curve, a second test after 3-4 h may bring clarification [31] .
If an operation cannot be delayed, the further approach is based on the NOAC plasma level, provided there are no other obstacles. For the interpretation of the plasma level values, the time of last NOAC intake and renal function are important. Only little data is available on the relation between NOAC plasma levels and the bleeding risk in surgical interventions. Levels < 30 ng/ml are considered safe for high bleeding risk interventions, whereas levels > 200 ng/ml are associated with a significant bleeding risk [52, 53] .
With plasma levels between 30 and 200 ng/ml, each case needs to be assessed individually, depending on the bleeding risk [29, 52] (fig. 1 ).
Spinal and Epidural Anesthesia in Patients Treated with NOACs
Guidelines that tackle NOAC management in neuraxial anesthesia make different recommendations about when to stop and when to resume these drugs before and after an intervention. The French Group on Perioperative Hemostasis (GIHP) for example recommends not to perform regional anesthesia techniques as long as a NOAC concentration is still prevalent [55] . Other recommendations suggest different timing schemes of cessation and re-initiation of anticoagulant treatment [56] [57] [58] , or, depending on the type of anesthesia, if discontinuation is even necessary at all [56] .
No definite evidence is available on this topic. The authors of this paper made a consensus-based conclusion: Both neuraxial puncture and the removal of a catheter have a comparable bleeding risk. The NOAC-free interval before these procedures corresponds with the surgical interventions with high bleeding risk, i.e. at least 5 half-lives (table 7) .
Deep nerve blocks like psoas compartment or infraclavicular blocks are considered to carry the same bleeding risk as spinal and epidural anesthesia.
Re-Start of NOACs after Intervention
Same as before when undergoing surgery, the management of anticoagulation after an intervention needs to balance the bleeding risk of the intervention and the thromboembolic risk of the patient. The drug-specific guidelines indicate re-initiation of anticoagulation as soon as sufficient hemostasis has been accomplished (table 8) [6] [7] [8] [9] .
In patients at high risk of thromboembolism, postoperative bridging with low-molecular-weight heparin or intravenous unfractionated heparin (according to institution protocol) can be considered until therapeutic anticoagulation can be re-introduced [59] ; a reduced dose (e.g. rivaroxaban 1 × 10 mg/day) or mechanical prophylaxis such as intermittent pneumatic compression can also be considered [59] .
Overdoses, Intoxications and Bleeding
Management of Overdoses and Intoxications
Overdoses of NOACs may occur in worsening of renal or hepatic function, incidentally or with suicidal intentions. If the elimination of the drug is not significantly reduced, the relatively short half-life of NOACs is an advantage compared to VKAs. In an unclear situation it may be helpful to determine plasma levels. Countermeasures may be considered, depending on the situation (table 9).
Management of Active Bleeding
When bleeding occurs, it is important to first assess the event according to severity of blood loss and location. Once more, it would be important to know the time of last intake and type of NOAC used as well as other factors that might influence plasma concentration and hemostasis [29] . In most non-life-threatening bleeding events, the temporary discontinuation of the NOAC and supportive care are sufficient to control the problem [61] . In a study with patients using rivaroxaban, even the majority of major bleedings (as defined by the International Society on Thrombosis and Hemostasis) could be managed with local therapy or red blood cell transfusions, with only 37% requiring an intervention or surgery [62] .
If the clinical situation calls for a more urgent procedure, specific or non-specific reversal agents can be considered [63] .
Currently, only dabigatran can be counteracted with a direct (or specific) reversal agent, idarucizumab (approved 2015 in the US and Europe and 2016 in Switzerland). It is highly important to repeat all coagulation tests 10 min after the administration of idarucizumab, because only then other coagulation problems of the patient can be clearly diagnosed. For FXa inhibitors the reversal agent andexanet alfa may soon be available (approved May 2018 in the US). Should a direct reversal agent not be available, the Swiss Society for Anesthesiology and Reanimation recommends the administration of tranexamic acid and potentially desmopressin to attempt a normalization of hemostasis, before using concentrates with pro-coagulant factors such as prothrombin complex concentrate (PCC) in severe bleeding [31, 64] . Activated PCC should only be considered in a patient with life-threatening, intractable bleeding [29, 63] .
Once the bleeding has been stopped, thromboembolic prophylaxis needs to be restarted in all patients as soon as possible, as patients under oral anticoagulation are particularly prone to thrombosis and thromboembolic complications (table 10) .
Outlook
Currently under investigation are two more reversal agents, andexanet alfa (targeting all FXas) and PER977 (or aripazine or ciraparantag, targeting FXa inhibitors, dabigatran and heparins) [61] . 
